Replies to post #32 on Asterias Biotherapeutics, Inc. (AST)

[tradetrak]

Gern sold their entire stem cell IP portfolio to Biotime (BTX), including two major product candidates in clinical trials - one is a cancer vaccine and the other remylinates nerve tissues. Biotime spun off Asterias as a subsidiary to continue the development of these two products both of which have mind blowing potential - if the next phases of the clinical trials continue to show positive results. BTX & GERN, to a much lesser degree, holds a substantial portion of AST shares. Many of the key people in BTX are former GERN leadership personell.
This press release came out today which, I believe, is why the stock is soaring.
http://investor.biotimeinc.com/phoenix.zhtml?c=83805&p=irol-newsArticle&ID=2038099